Citadel Advisors’s AtriCure ATRC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.49M | Sell |
87,347
-155,394
| -64% | -$5.3M | ﹤0.01% | 5629 |
|
|
2025
Q4 | $9.6M | Buy |
242,741
+197,242
| +434% | +$7.23M | ﹤0.01% | 3303 |
|
|
2025
Q3 | $1.6M | Sell |
45,499
-89,236
| -66% | -$3.07M | ﹤0.01% | 6520 |
|
|
2025
Q2 | $4.42M | Sell |
134,735
-54,748
| -29% | -$1.78M | ﹤0.01% | 4339 |
|
|
2025
Q1 | $6.11M | Sell |
189,483
-5,499
| -3% | -$204K | ﹤0.01% | 3563 |
|
|
2024
Q4 | $5.96M | Buy |
194,982
+36,239
| +23% | +$1.17M | ﹤0.01% | 3689 |
|
|
2024
Q3 | $4.45M | Buy |
158,743
+5,036
| +3% | +$124K | ﹤0.01% | 4123 |
|
|
2024
Q2 | $3.5M | Sell |
153,707
-153,610
| -50% | -$3.55M | ﹤0.01% | 4328 |
|
|
2024
Q1 | $9.35M | Buy |
307,317
+1,468
| +0.5% | +$49.2K | ﹤0.01% | 3030 |
|
|
2023
Q4 | $10.9M | Buy |
305,849
+210,251
| +220% | +$7.82M | ﹤0.01% | 2718 |
|
|
2023
Q3 | $4.19M | Sell |
95,598
-215,589
| -69% | -$10.5M | ﹤0.01% | 3947 |
|
|
2023
Q2 | $15.4M | Sell |
311,187
-28,806
| -8% | -$1.33M | ﹤0.01% | 2154 |
|
|
2023
Q1 | $14.1M | Buy |
339,993
+210,127
| +162% | +$8.72M | ﹤0.01% | 2348 |
|
|
2022
Q4 | $5.76M | Buy |
129,866
+66,988
| +107% | +$2.8M | ﹤0.01% | 3623 |
|
|
2022
Q3 | $2.46M | Buy |
62,878
+3,375
| +6% | +$154K | ﹤0.01% | 5188 |
|
|
2022
Q2 | $2.43M | Sell |
59,503
-151,745
| -72% | -$7.19M | ﹤0.01% | 5165 |
|
|
2022
Q1 | $13.9M | Sell |
211,248
-152,395
| -42% | -$9.88M | ﹤0.01% | 2475 |
|
|
2021
Q4 | $25.3M | Sell |
363,643
-137,054
| -27% | -$9.96M | 0.01% | 1767 |
|
|
2021
Q3 | $34.8M | Sell |
500,697
-328,120
| -40% | -$25.3M | 0.01% | 1435 |
|
|
2021
Q2 | $65.8M | Buy |
828,817
+308,656
| +59% | +$22.4M | 0.01% | 927 |
|
|
2021
Q1 | $34.1M | Buy |
520,161
+253,698
| +95% | +$15.6M | 0.01% | 1400 |
|
|
2020
Q4 | $14.8M | Sell |
266,463
-8,341
| -3% | -$361K | ﹤0.01% | 2142 |
|
|
2020
Q3 | $11M | Buy |
274,804
+34,747
| +14% | +$1.47M | ﹤0.01% | 2176 |
|
|
2020
Q2 | $10.8M | Buy |
240,057
+130,483
| +119% | +$5.68M | ﹤0.01% | 2124 |
|
|
2020
Q1 | $3.68M | Buy |
109,574
+74,234
| +210% | +$2.67M | ﹤0.01% | 3154 |
|
|
2019
Q4 | $1.15M | Sell |
35,340
-77,061
| -69% | -$2.19M | ﹤0.01% | 5339 |
|
|
2019
Q3 | $2.8M | Sell |
112,401
-56,879
| -34% | -$1.62M | ﹤0.01% | 3956 |
|
|
2019
Q2 | $5.05M | Sell |
169,280
-46,214
| -21% | -$1.35M | ﹤0.01% | 3059 |
|
|
2019
Q1 | $5.77M | Buy |
215,494
+78,037
| +57% | +$2.37M | ﹤0.01% | 2794 |
|
|
2018
Q4 | $4.21M | Sell |
137,457
-13,256
| -9% | -$413K | ﹤0.01% | 3029 |
|
|
2018
Q3 | $5.28M | Sell |
150,713
-7,305
| -5% | -$231K | ﹤0.01% | 2931 |
|
|
2018
Q2 | $4.28M | Buy |
158,018
+7,289
| +5% | +$171K | ﹤0.01% | 2973 |
|
|
2018
Q1 | $3.09M | Sell |
150,729
-227,910
| -60% | -$4.12M | ﹤0.01% | 3105 |
|
|
2017
Q4 | $6.91M | Buy |
378,639
+44,074
| +13% | +$873K | ﹤0.01% | 2109 |
|
|
2017
Q3 | $7.48M | Buy |
334,565
+308,708
| +1,194% | +$6.98M | 0.01% | 1885 |
|
|
2017
Q2 | $627K | Sell |
25,857
-13,835
| -35% | -$294K | ﹤0.01% | 4795 |
|
|
2017
Q1 | $760K | Buy |
+39,692
| New | +$695K | ﹤0.01% | 4407 |
|
|
2016
Q2 | – | Sell |
-46,726
| Closed | -$712K | – | 6803 |
|
|
2016
Q1 | $786K | Buy |
+46,726
| New | +$822K | ﹤0.01% | 3777 |
|
|
2015
Q4 | – | Sell |
-27,606
| Closed | -$605K | – | 8706 |
|
|
2015
Q3 | $605K | Buy |
+27,606
| New | +$690K | ﹤0.01% | 4527 |
|
|
2014
Q1 | – | Sell |
-25,239
| Closed | -$471K | – | 7833 |
|
|
2013
Q4 | $471K | Buy |
+25,239
| New | +$367K | ﹤0.01% | 4096 |
|
Other funds holding ATRC
HRCM
VPM
VCM
NAMI
Citadel Advisors's ATRC Position: Q1 2026 in Review
Citadel Advisors reduced its AtriCure (ATRC) stake by 64% in Q1 2026, selling an estimated $5.3M and leaving 87,347 shares worth $2.49M. The position accounts for ﹤0.01% of the portfolio, ranked #5629.
Citadel Advisors first reported a position in ATRC in Q4 2013 and has held it in 40 quarters since. The position peaked at $65.8M in Q2 2021. 223 funds tracked by Wall St. Rank hold ATRC as of Q1 2026.
- Citadel Advisors held 87,347 shares of AtriCure worth $2.49M as of Q1 2026.
- Citadel Advisors sold 155,394 AtriCure shares in Q1 2026, an estimated $5.3M.
- AtriCure made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5629 holding.
- Citadel Advisors first reported a position in AtriCure in Q4 2013 and has held it in 40 quarters since.
- Citadel Advisors's AtriCure position peaked at $65.8M in Q2 2021.
- 223 funds tracked by Wall St. Rank held AtriCure as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.